Which has better valuation & earnings, CRBP or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is CRBP or TECX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Tectonic Therapeutic N/A -32.33% -30.92%

Which has higher earnings & valuation, CRBP or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is CRBP or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Monopar Therapeutics N/A -12.84% -12.57%

Which has stronger earnings & valuation, CRBP or EIKN?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Eikon Therapeutics N/A N/A N/A -$2.46 N/A

Is CRBP or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Eikon Therapeutics N/A N/A N/A

Which has stronger earnings & valuation, CRBP or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is CRBP or RLMD more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Relmada Therapeutics N/A -71.22% -64.46%

Corbus Pharmaceuticals (CRBP) Competitors

$9.01 -0.02 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$9.14 +0.13 (+1.39%)

As of 07:36 PM Eastern

Compare

CRBP vs. TECX, FDMT, MNPR, EIKN, and RLMD

Should you buy Corbus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corbus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corbus Pharmaceuticals include Tectonic Therapeutic (TECX), 4D Molecular Therapeutics (FDMT), Monopar Therapeutics (MNPR), Eikon Therapeutics (EIKN), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

How does Corbus Pharmaceuticals compare to Tectonic Therapeutic?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Tectonic Therapeutic's return on equity of -32.33% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Corbus Pharmaceuticals has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market.

Corbus Pharmaceuticals currently has a consensus price target of $40.67, suggesting a potential upside of 351.35%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 144.31%. Given Corbus Pharmaceuticals' higher possible upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat Tectonic Therapeutic's score of 1.08 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Very Positive
Tectonic Therapeutic	Positive

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tectonic Therapeutic beats Corbus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

4D Molecular Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market.

Corbus Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Corbus Pharmaceuticals has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.17	-$140.11M	-$2.57	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

4D Molecular Therapeutics currently has a consensus price target of $29.88, indicating a potential upside of 155.78%. Corbus Pharmaceuticals has a consensus price target of $40.67, indicating a potential upside of 351.35%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 7 mentions for 4D Molecular Therapeutics and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat 4D Molecular Therapeutics' score of 0.47 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
4D Molecular Therapeutics	Neutral
Corbus Pharmaceuticals	Very Positive

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

4D Molecular Therapeutics beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Monopar Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Corbus Pharmaceuticals currently has a consensus target price of $40.67, suggesting a potential upside of 351.35%. Monopar Therapeutics has a consensus target price of $108.75, suggesting a potential upside of 0.06%. Given Corbus Pharmaceuticals' higher possible upside, equities analysts clearly believe Corbus Pharmaceuticals is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

In the previous week, Monopar Therapeutics had 5 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 6 mentions for Monopar Therapeutics and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat Monopar Therapeutics' score of 0.68 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Very Positive
Monopar Therapeutics	Positive

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Corbus Pharmaceuticals has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Monopar Therapeutics' return on equity of -12.84% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Summary

Monopar Therapeutics beats Corbus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Eikon Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Eikon Therapeutics' return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Eikon Therapeutics	N/A	N/A	N/A

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

In the previous week, Eikon Therapeutics had 2 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for Eikon Therapeutics and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat Eikon Therapeutics' score of 0.17 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Very Positive
Eikon Therapeutics	Neutral

Corbus Pharmaceuticals currently has a consensus target price of $40.67, suggesting a potential upside of 351.35%. Eikon Therapeutics has a consensus target price of $25.20, suggesting a potential upside of 156.10%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Eikon Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Relmada Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Corbus Pharmaceuticals has a beta of 2.55, meaning that its stock price is 155% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Corbus Pharmaceuticals' return on equity of -70.89% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

In the previous week, Relmada Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat Relmada Therapeutics' score of 0.44 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Very Positive
Relmada Therapeutics	Neutral

Corbus Pharmaceuticals currently has a consensus target price of $40.67, suggesting a potential upside of 351.35%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 93.24%. Given Corbus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Relmada Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$167.31M	$3.01B	$6.78B	$12.56B
Dividend Yield	N/A	2.08%	2.68%	9.46%
P/E Ratio	-1.55	19.41	27.12	24.35
Price / Sales	N/A	361.61	487.66	77.47
Price / Cash	N/A	56.68	48.63	60.00
Price / Book	1.07	4.26	10.82	6.31
Net Income	-$78.54M	$65.13M	$3.59B	$331.55M
7 Day Performance	-5.65%	-2.24%	-1.21%	0.15%
1 Month Performance	8.29%	2.45%	3.13%	-0.68%
1 Year Performance	11.79%	23.80%	29.12%	20.73%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	3.7126 of 5 stars	$9.01 -0.2%	$40.67 +351.4%	+8.0%	$167.31M	N/A	N/A	40	Positive News
TECX Tectonic Therapeutic	2.7363 of 5 stars	$35.78 +1.6%	$79.40 +121.9%	+50.6%	$667.13M	N/A	N/A	120	News Coverage Positive News
FDMT 4D Molecular Therapeutics	1.8568 of 5 stars	$12.60 -1.0%	$29.88 +137.1%	+167.1%	$655.33M	$85.21M	N/A	120	News Coverage Insider Trade
MNPR Monopar Therapeutics	1.3192 of 5 stars	$97.16 +0.0%	$108.75 +11.9%	+128.2%	$650.97M	N/A	N/A	10	News Coverage Analyst Downgrade
EIKN Eikon Therapeutics	2.3186 of 5 stars	$11.92 -0.9%	$25.20 +111.4%	N/A	$645.34M	N/A	N/A	384

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. TECX, FDMT, MNPR, EIKN, and RLMD

How does Corbus Pharmaceuticals compare to Tectonic Therapeutic?

Summary

How does Corbus Pharmaceuticals compare to 4D Molecular Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Monopar Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Eikon Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. TECX, FDMT, MNPR, EIKN, and RLMD

How does Corbus Pharmaceuticals compare to Tectonic Therapeutic?

Is CRBP or TECX more profitable?

Which has better valuation & earnings, CRBP or TECX?

Which has more risk & volatility, CRBP or TECX?

Do analysts prefer CRBP or TECX?

Does the media prefer CRBP or TECX?

Do institutionals and insiders hold more shares of CRBP or TECX?

Summary

How does Corbus Pharmaceuticals compare to 4D Molecular Therapeutics?

Which has more volatility and risk, FDMT or CRBP?

Is FDMT or CRBP more profitable?

Which has preferable valuation & earnings, FDMT or CRBP?

Do analysts rate FDMT or CRBP?

Does the media refer more to FDMT or CRBP?

Do institutionals and insiders believe in FDMT or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Monopar Therapeutics?

Do analysts prefer CRBP or MNPR?

Does the media favor CRBP or MNPR?

Do institutionals and insiders hold more shares of CRBP or MNPR?

Which has more risk & volatility, CRBP or MNPR?

Which has higher earnings & valuation, CRBP or MNPR?

Is CRBP or MNPR more profitable?

Summary

How does Corbus Pharmaceuticals compare to Eikon Therapeutics?

Is CRBP or EIKN more profitable?

Which has stronger earnings & valuation, CRBP or EIKN?

Does the media prefer CRBP or EIKN?

Do analysts recommend CRBP or EIKN?

Do insiders & institutionals hold more shares of CRBP or EIKN?

Summary

How does Corbus Pharmaceuticals compare to Relmada Therapeutics?

Which has more volatility & risk, CRBP or RLMD?

Is CRBP or RLMD more profitable?

Which has stronger earnings & valuation, CRBP or RLMD?

Does the media prefer CRBP or RLMD?

Do analysts recommend CRBP or RLMD?

Do insiders & institutionals hold more shares of CRBP or RLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools